E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Rationale The development of consensus guidelines for interpretation of Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide more consistent reports in clinical practice. The standardization of PSMA-PET interpretation may also contribute to increasing the...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2021-05, Vol.48 (5), p.1626-1638
Main Authors: Ceci, Francesco, Oprea-Lager, Daniela E., Emmett, Louise, Adam, Judit A., Bomanji, Jamshed, Czernin, Johannes, Eiber, Matthias, Haberkorn, Uwe, Hofman, Michael S., Hope, Thomas A., Kumar, Rakesh, Rowe, Steven P., Schwarzenboeck, Sarah M., Fanti, Stefano, Herrmann, Ken
Format: Article
Language:English
Subjects:
Antigens
Cardiology
Clinical trials
Disease management
Guidelines
Humans
Imaging
Male
Medicine
Medicine & Public Health
Nuclear Medicine
Oncology
Oncology – Genitourinary
Orthopedics
Physicians
Positron emission
Positron emission tomography
Positron Emission Tomography Computed Tomography
Prostate
Prostate cancer
Prostatic Neoplasms - diagnostic imaging
Radiology
Reproducibility of Results
Standardization
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale The development of consensus guidelines for interpretation of Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide more consistent reports in clinical practice. The standardization of PSMA-PET interpretation may also contribute to increasing the data reproducibility within clinical trials. Finally, guidelines in PSMA-PET interpretation are needed to communicate the exact location of findings to referring physicians, to support clinician therapeutic management decisions. Methods A panel of worldwide experts in PSMA-PET was established. Panelists were selected based on their expertise and publication record in the diagnosis or treatment of PCa, in their involvement in clinical guidelines and according to their expertise in the clinical application of radiolabeled PSMA inhibitors. Panelists were actively involved in all stages of a modified, nonanonymous, Delphi consensus process. Results According to the findings obtained by modified Delphi consensus process, panelist recommendations were implemented in a structured report for PSMA-PET. Conclusions The E-PSMA standardized reporting guidelines, a document supported by the European Association of Nuclear Medicine (EANM), provide consensus statements among a panel of experts in PSMA-PET imaging, to develop a structured report for PSMA-PET in prostate cancer and to harmonize diagnostic interpretation criteria.
ISSN:1619-7070
1619-7089
1619-7089
DOI:10.1007/s00259-021-05245-y